Home > Insider Trading > Filing (0000899243-17-008729)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501989	Cytomx Therapeutics Inc.	CTMX	Pharmaceutical Preparations (2834)	273521219

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1620014	Neil Exter	29 Newbury Street, 3Rd Floor Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2017-03-23	0	$0.00	0	No	4	S	Indirect	See footnote
Common Stock	Disposition	2017-03-27	0	$0.00	0	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,199	Indirect	By The Neil Exter 2012 Irrevocable

Footnotes

On March 23, 2017, Third Rock Ventures, L.P. ("TRV") sold 1,000,000 shares of Common Stock of the Issuer. The shares were sold in one execution at a price per share of $17.0002.
After the transaction referenced in note (1), TRV owned 5,820,348 shares of Common Stock of the Issuer.
The reporting person is a partner of Third Rock Ventures GP, L.P., which is the general partner of TRV. The reporting person disclaims beneficial ownership over the shares held by TRV, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
On March 27, 2017, TRV sold 650,000 shares of Common Stock of the Issuer. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive, and at a weighted average price of $18.0003. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
After the transaction referenced in note (4), TRV owned 5,170,348 shares of Common Stock of the Issuer.